Drug combo shrinks tumors before surgery, aims to stop Cancer's return
NCT ID NCT02231775
Summary
This study tested a two-part drug treatment for people with stage IIIB or IIIC melanoma that has a specific genetic change (BRAF V600 mutation). Patients took the drugs dabrafenib and trametinib for 8 weeks before surgery to try to shrink the tumor, then continued the drugs for about 44 weeks after surgery to try to kill any remaining cancer cells and prevent the cancer from coming back. The main goal was to see if patients whose tumors disappeared completely after the pre-surgery drugs lived longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.